Publications by authors named "Y Kikushige"
In this study, we investigated the measurable residual leukemic stem cell (MR-LSC) population after allogeneic stem cell transplantation (allo-SCT) for high-risk acute myeloid leukemia (AML), utilizing T-cell immunoglobulin mucin-3 (TIM-3) expression as a functional marker of AML leukemic stem cells (LSCs). Analysis of the CD34CD38 fraction of bone marrow cells immediately after achievement of engraftment revealed the presence of both TIM-3LSCs and TIM-3 donor hematopoietic stem cells (HSCs) at varying ratios. Genetic analysis confirmed that TIM-3 cells harbored patient-specific mutations identical to those found in AML clones, whereas TIM-3 cells did not, indicating that TIM-3CD34CD38 cells represent residual AML LSCs.
View Article and Find Full Text PDFIntroduction: Castleman disease (CD) is a benign lymphoproliferative disease causing severe systemic inflammation. Interleukin-6 (IL-6) is a major pathogenesis of multicentric CD (MCD), but only 30-60% of patients respond to IL-6 inhibitors. Novel agents for IL-6 inhibitor-refractory cases are needed.
View Article and Find Full Text PDFArticle Synopsis
- * The results showed significant improvement in patient responses, with complete or better responses increasing from 19.9% after induction to 62.4% after maintenance, alongside a 3-year progression-free survival rate of 83.5% and overall survival rate of 92.5%.
- * While the treatment was tolerable, around 30% of patients experienced severe side effects, and those with high-risk cytogenetics
Article Synopsis
- The human leukocyte antigen (HLA) supertype classification is linked to the outcomes of viral infections and autoimmune diseases, but its significance in single-unit cord blood transplantation (sCBT) was unclear.
- A study of 1603 sCBT patients in Japan found that mismatches in the HLA-B supertype were associated with worse patient prognoses, leading to higher relapse rates.
- Despite the importance of HLA-B supertype matches for improving patient outcomes, these mismatches did not affect the incidences of acute or chronic graft-versus-host disease.
Article Synopsis
- Immunomodulatory drugs (IMiDs) are important treatments for myeloma and myelodysplastic syndrome, but they increase the risk of thrombosis, which can lead to serious complications.
- This study explored how IMiDs affect thrombosis by examining cereblon substrates in human megakaryocytes, finding that thrombospondin-1 (THBS-1) accumulates abnormally when IMiDs interfere with its degradation.
- The results indicate that the accumulation of THBS-1, caused by disrupted cereblon interaction due to IMiDs, may contribute to the increased risk of thromboembolism in patients undergoing IMiD treatment.